Checkmate Pharmaceuticals (NASDAQ:CMPI) Releases Quarterly Earnings Results, Misses Expectations By $0.44 EPS

Checkmate Pharmaceuticals (NASDAQ:CMPI) issued its quarterly earnings results on Wednesday. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.44), Zacks reports.

Shares of CMPI stock opened at $11.26 on Friday. Checkmate Pharmaceuticals has a 52-week low of $8.61 and a 52-week high of $16.49. The firm has a fifty day simple moving average of $11.61.

A number of analysts have weighed in on CMPI shares. Jefferies Financial Group started coverage on shares of Checkmate Pharmaceuticals in a report on Tuesday, September 1st. They issued a “buy” rating and a $22.00 price target for the company. BMO Capital Markets started coverage on shares of Checkmate Pharmaceuticals in a report on Tuesday, September 1st. They issued an “outperform” rating and a $32.00 price target for the company. BTIG Research started coverage on shares of Checkmate Pharmaceuticals in a report on Tuesday, September 1st. They issued a “buy” rating and a $29.00 price target for the company. Finally, Bank of America began coverage on shares of Checkmate Pharmaceuticals in a report on Tuesday, September 1st. They issued a “neutral” rating and a $19.00 price target for the company.

Checkmate Pharmaceuticals Company Profile

Checkmate Pharmaceuticals, Inc, a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor's ability to mute the immune response.

Further Reading: Net Margin – Understanding the Different Kinds of Profit

Receive News & Ratings for Checkmate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkmate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.